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Abstract
In order to find common genetic abnormalities that may
identify loci of genes involved in the development of
adenoid cystic carcinoma (ACC), we investigated DNA
copy number changes in 24 of these tumors by
comparative genomic hybridization (CGH). Our results
indicate that unlike many carcinomas, ACCs have
relatively few changes in DNA copy number overall.
Twenty tumors had DNA copy number changes, which
were mostly restricted to a few chromosomal arms. A
frequent novel finding was the loss of DNA copy number
in chromosome 12q (eight tumors, 33%) with the
minimal common overlapping region at 12q12–q13.
Deletion in this region has not been reported to be
frequent in other types of cancer analyzed by CGH. In
addition, deletions in 6q23-qter and 13q21–q22 and
gains of chromosome 19 were observed in 25% to 38%
of ACCs. Deletion of 19q, previously reported in a small
series of ACC, was not identified in the current group of
carcinomas. The current CGH results for chromosomes
12 and 19 were confirmed by microsatellite allelotyping.
These results indicate that DNA copy number losses in
12q may be important in the oncogenesis of ACC and
suggest that the 12q12–q13 region may harbor a new
tumor-suppressor gene. Neoplasia (2001) 3, 173–178.
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Introduction
Adenoid cystic carcinoma (ACC) is the most common
malignant tumor of the submandibular and minor salivary
glands [1,2], and also arises in other anatomic sites including
the breast and vulva. Despite resection with and without
postoperative irradiation, about 40% to 60% of patients with
salivary ACC develop distant metastases [1]. The clinical
course is often lengthy, however, and disease-specific
mortality frequently occurs 10 to 20 years after therapy.
ACC has a proclivity for invading nerves, a feature which,
while certainly not unique, suggests specific molecular
pathways leading to neurotropism. The neoplasm typically
lacks the ability to metastasize to lymph nodes, preferring the
hematogenous route. ACC characteristically shows features
of myoepithelial differentiation and produces abundant
basement membrane material and glycosaminoglycans,
which may be linked to novel genetic mechanisms of
differentiation.
Genetic changes that lead to the initiation and progression
of ACC are poorly characterized. Cytogenetic studies have
shown a relatively limited number of changes, the most
frequent including alterations of 6q21–q24 (deletions or
translocations), translocations of 9p13–p23, and, to a less
extent, gains of chromosomes 7 and 8 [3–5]. After the
detection of chromosome 17p13 deletions by fluorescent in
situ hybridization [6], loss of heterozygosity (LOH) analysis
in ACC has shown abnormalities of the p53 gene locus in up
to half of ACCs [7,8]. In a low-resolution study of 10 ACCs,
LOH analysis showed loss in 1p, 2p, 6q, and 17q in 20% to
30% and in 19q in 40% of cases [9]. High- resolution deletion
mapping of 6q in six cases of ACC showed LOH in either
6q23 or 6q27 in two tumors [10]. In other cancers,
comparative genomic hybridization (CGH) combined with
LOH analysis has been shown to be a very powerful
technique in identifying putative tumor-suppressor loci [11].
To date, however, there are no published surveys of global
DNA copy number changes as detected by CGH for ACC.
To obtain a comprehensive profile of the DNA copy
number changes in ACC, we screened 24 cases for DNA
copy number alterations in whole tumor genomes by CGH,
and further investigated chromosomes 19 and 12 for genetic
alterations using microsatellite LOH analysis.
Materials and Methods
Tumors
This study was approved by the Institutional Review Board
of the University of Virginia Health System. Twenty- four
formalin- fixed, paraffin-embedded cases of ACC were
obtained from the files of the Division of Surgical Pathology
at the University of Virginia Health System. Sixteen patients
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were women and eight were men. The age range at
diagnosis was 33 to 73 years (median 57 years). Ten
tumors arose in the major salivary glands ( lacrimal gland
included), whereas 14 tumors developed in the minor
salivary glands. The tumors were graded according to
Szanto et al. [12 ] as lesions with no solid component (grade
1), <30% solid areas (grade 2), and >30% solid component
(grade 3). Nine ACCs were grade 1, nine were grade 2, and
six were grade 3. Pathologic stage was recorded based on
the AJCC criteria [13]. Eight tumors were stage I, five were
stage II, one was stage III, and 10 were stage IV. Patient
follow-up data were obtained from the McIntire Tumor
Registry at the University of Virginia Health System. Follow-
up time ranged from 0.3 to 13.5 years (median 5.5 years)
with 2 of 24 patients being diagnosed recently. Of the
remaining patients, nine had developed metastases, while
13 had not. For the LOH study, five additional tumors
collected from two women and three men were allelotyped
using chromosomes 19 and 12 markers. Of these five
tumors, one was grade 1, one was grade 2, and three were
grade 3. Pathologic stage of these additional tumors included
one stage I tumor, two stage IV tumors, and two tumors of
unknown stage.
CGH
As the minimum sensitivity requirement for CGH is 50% of
tumor material within a sample, paraffin -embedded tissue
sections were dissected to obtain an estimated minimum of
70% tumor cells. DNA from paraffin-embedded tissue
sections was extracted as previously described [14]. DNA
extracted from peripheral blood cells of a healthy donor,
along with DNA extracted from a gastric tumor with known
DNA copy number changes, were, respectively, used as a
negative and positive control in each CGH experiment. CGH
was performed according to standard procedures with a
modification using a mixture of fluorochromes conjugated to
dCTP and dUTP nucleotides for nick translation [15].
Hybridizations, washings, and ISIS digital image analysis
(MetaSystems, Altlussheim, Germany) were performed as
described elsewhere [16]. Results from our controls and
previous studies [16,17] indicated cut off levels of 1.17 and
0.85 for gains and losses, respectively. All CGH results were
confirmed using a 99% confidence interval. Intra-experiment
standard deviations for all positions in the CGH ratio profiles
were calculated from the variation of the ratio values of all
homologous chromosomes within the experiment. Confi-
Figure 1. Summary of the most frequent gains and losses of DNA sequences
in 20 ACCs with abnormal DNA copy number. Gains are on the right side of the
chromosome ideogram and losses are on the left. A single line represents
each tumor sample.
Figure 2. LOH analysis using chromosome 12 markers in 29 ACCs. The microsatellite markers used are listed on the left, in order from pter ( top ) to qter ( bottom ).
The results of the assays are shown as indicated in the key. The black squares indicate deleted loci. Deletions were found in 10 of 29 cancers (34%). The majority of
losses were found at the D12S1301 marker, having loss in 6 of 10 cancers with deletions (60%) followed by the D12S391 marker having loss in 5 of 10 cancers with
deletions ( 50%). CGH results are from Table 1.
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dence intervals for the ratio profiles were then computed by
combining them with an empirical inter -experiment standard
deviation and by estimating error probabilities based on the
t -distribution.
Microsatellite LOH Assays
Chromosome 12 was selected for LOH analysis as CGH
results of the present study showed a novel area of loss on
this chromosome. Twenty-nine ACCs that were micro-
dissected to 75% to 95% purity were chosen for LOH
analysis. This group included 24 tumors that had been
analyzed by CGH. Matched normal tissue was dissected
for each cancer and DNA was extracted from both tissues
as previously published [18]. MapPairs primers for micro-
satellite markers were obtained from Research Genetics
(Huntsville, AL). Markers used on chromosome 12 were
D12S391, D12S1301, and D12S1064 (Figure 2 ). The
same panel of tumors was assayed for LOH using
chromosome 19 markers D19S414, D19S220, D19S223,
D19S246, D19S589, D19S254, and D19S210. Radiolabeled
polymerase chain reaction (PCR) amplification, gel electro-
phoresis, autoradiography of microsatellite markers, and
LOH determination were performed as previously described
[19]. A tumor was determined to have undergone LOH at a
particular locus only if the predominant band(s) associated
with one allele showed a diminution in intensity of 50% or
more in the tumor relative to normal [20], although most
assays showed a complete or virtually complete absence of
one allele in the tumor DNA in comparison to that of the
matching normal DNA (Figure 3 ). All losses were confirmed
in an independent PCR assay. In a subset of cases, duplex
PCR was performed with primers to a portion of the  -2-
microglobulin gene (B2M) to control for the presence of DNA
of sufficient size in the genomic preparations to amplify the
microsatellite alleles. The primers for this 264-bp product
are: 50 -ATTCACCCCCACTGAAAAAG-30 (F) and 50 -
ACTAATCTGATCTTTACGAAC-30 (R).
Statistics
The relationship between tumor site (major versus minor
salivary glands), grade, stage, and the presence of meta-
stasis was compared with the most frequent CGH gains or
losses using Fisher’s exact test ( two- tailed). The relation-
ship between the number of DNA copy alterations and tumor
grade was examined using the unpaired t - test.
Results
CGH
Changes of DNA copy number were detected in 20
tumors. The average number of changes per tumor was 2.7.
Losses of DNA sequences were more frequent than gains,
and no high- level amplifications were seen. Grade 3 tumors
had more changes (mean 5.7) than grades 1 and 2
neoplasms (mean 1.8, P<.001). The most frequent abnor-
malities included losses at 6q (25%), 12q (33%), and 13q
(25%), and gains in chromosome 19 (38%). Table 1 shows
the results in detail. Figure 1 presents a summary of the most
common gains and losses of DNA sequences found in 20
ACCs with alterations in DNA copy number. There was no
correlation between tumor site (major or minor salivary
glands), grade, stage, or presence of metastasis with gain in
19 or loss in 6q, 12q, or 13.
Microsatellite LOH Analysis
Chromosome 12 was selected for LOH analysis to
confirm the finding of loss found by CGH at chromosome
12q12–q13. A microsatellite marker located within this
cytogenetic location and two other markers bounding this
region were used in a PCR amplification LOH assay
(Figure 2 ). Results from LOH analysis showed a complete
or virtually complete loss in all tumors with similar losses
by CGH (Figure 3 ). LOH results showed an overall loss of
34% on chromosome 12, with the greatest loss occurring
at the D12S1301 marker (30%) (Figures 2 and 3 ). The
D12S1301 marker is located at the same chromosome
12q12–q13 cytogenetic region showing CGH loss (Figure
2 ). Marker D12S391, located on the p arm of chromosome
12, showed loss in 5 of 15 informative cases, while the
D12S1064 marker, located on the q arm and distal to
D12S1301, showed loss in only 1 of 22 informative cases
(Figure 2 ). Of the 10 tumors demonstrating LOH, one of
these was not analyzed by CGH (sample 25), and five had
DNA copy number changes in 12q detected by CGH
(samples 8, 11, 13, 14, 18), with one of these having
12q21-qter loss and distal to the 12q12–q13 region
(sample 11). The other four tumors in Figure 2 did not
show DNA copy number changes when analyzed by CGH
(samples 5, 9, 16, 19). Sample 12 showed 12q12–q13
loss by CGH analysis, but did not show loss by LOH in any
of the three markers examined. CGH analyses also
showed DNA copy number changes at 12q in four tumors
(samples 13, 14, 20, 23), but LOH analysis showed these
to be not informative for 12q markers. Furthermore, two of
these (samples 13 and 14), in addition to samples 9 and
Figure 3. Autoradiographs showing specific examples of LOH for each of four
different ACCs on chromosome 12. (A ) Marker D12S391 for case 13. (B )
Duplex PCR with marker D12S391 and B2M for case 5. (C ) Marker
D12S1301 for case 16. (D ) Marker D12S1301 for case 18. Left lanes show
assays of non -neoplastic cells (N ); right lanes show assays of neoplastic
( tumor ) cells (T ). Solid arrows denote the microsatellite allele lost in the tumor
samples. In Panel B, the open arrow points to the B2M duplex PCR product,
which serves as a control for the presence of DNA fragments in the sample
preparation of sufficient size to amplify the larger allele in the microsatellite
PCR.
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19, had LOH at D12S391, as did case 5, which also had
LOH at D12S1301.
Chromosome 19 was selected for LOH analysis because
a previous study reporting deletion of this chromosome in
ACC [9] was not consistent with our CGH findings of only
gain of DNA copy number. Results from LOH analysis of
chromosome 19 did not show loss for any of the seven
markers, in agreement with our CGH results. The average of
informative microsatellite assays per case was 3.9.
Discussion
The loss of chromosome 12q12–q13 is a novel finding in
ACC. Such loss was the only detectable DNA copy number
change in three tumors in this study, suggesting that a gene
in this region plays a special role in ACC tumorigenesis.
Further investigation of chromosome 12 by LOH analysis
showed the overall loss on chromosome 12 to be similar to
that found by CGH and that this loss likely includes a locus
telomeric to D12S1301 since only 6 of 10 tumors with LOH
includedD12S1301. The finding of 12q loss by CGH analysis
alone for sample 12 also leads us to believe that the loss may
be telomeric to D12S1301. Interestingly, using the D12S391
marker, there was a high level of loss on the p arm of
chromosome 12, suggesting that this loss may involve a
relatively large area of chromosome 12 or perhaps, there is
more than one consensus region residing on this chromo-
some — one at 12p11–13 and the other(s) at 12q. The fact,
that LOH analysis alone showed loss on the p arm for four
tumors (samples 9, 13, 14, and 19), suggests that this area
may be involved by deletions too small for identification by
CGH. The potential for loss on the q arm of chromosome 12
may perhaps extend further than that shown by LOH
analyses because the two 12q markers are non- informative
for a number of tested samples. The small microsatellite
panel used in this study served only as an independent
confirmation of the finding by CGH of deletions on
chromosome 12. Further LOH studies using higher-density
allelotyping of microsatellite markers are required to con-
clusively determine the number and localization of consen-
sus regions on chromosome 12.
Although a recent literature review of 283 CGH studies
showed that chromosome 12 deletions were not frequent in
any of the 73 tumor entities analyzed [21], one study using
microsatellite LOH assays found evidence of genetic
deletion at 12q in salivary gland pleomorphic adenomas
and in the adenoma component of carcinoma ex-pleomor-
phic adenoma [22]; the authors concluded that LOH at 12q
may identify a subset of adenomas with the potential to
progress to carcinoma. Although the majority of carcinomas
arising in pleomorphic adenomas showed loss distal to the
12q12–q13 region, some of the deletions did extend to this
locus, and in two cases, this region was the sole area of
deletion. Interestingly, a translocation of 12q12–q13 in a
Table 1. Clinical, Histological, and CGH Karyotype Findings for 24 ACCs.
Case Age /Sex Tumor Site Grade /Stage CGH Karyotype
Losses Gains
1 49 /F trachea 1 / I 6q22.3–q23, X –
2 68 /M submandibular 1 / I N N
3 54 /F trachea 1 / I – 15, 16, 17, 19
4 70 /M soft palate 1 / I 6q23 -qter, 9q31 -qter, 13q14–q22 19
5 54 /F submandibular 1 / II 8q11–q13, 9p 3q13.3–q23
6 53 /M maxilla 1 / III 6q23 -qter –
7 65 /M parotid 1 / IV 13q21 -qter, 14 –
8 64 /M maxilla 1 / IV 12q12–q14 16, 19
9 58 /F parotid 1 / IV 9p21 -pter 19
10 57 /F soft palate 2 / I N N
11 50 /F floor of mouth 2 / I 12q21.3 - qter –
12 36 /F bronchus 2 / IA 6q11–q23, 12q12–q14,
13q14–q31
19
13 66 /F nasal septum 2 / II 12q12–q15 –
14 64 /M parotid 2 / IV 12q12–q21.2, 13q14–q31 –
15 33 /F parotid 2 / IV N N
16 48 /F tongue base 2 / IVA N N
17 43 /F trachea 2 / IIIB 14 22
18 72 /F tongue 2 / unknown 12q12–q13 –
19 69 /M soft palate 3 / II – 8
20 57 /F parotid 3 / IV 6q11–q23, 9p21 -pter, 12q15–q21,
13q13–q31
19
21 54 /F maxilla 3 / IVA 1p35 -pter, 1q41 -qter, 5, 11p 1p11–p34, 1q11–q32, 7, 9p,
11q12–q13
22 50 /M palate 3 / IVC 6q23 -qter, 9q, 11q21–q23 9p, 19, 22
23 73 /F lacrimal gland 3 /T2 N0 M0 1p33 -pter, Xp21 -pter, 6q22.2–q23,
7p13–p21.2, 12q12–q13, 13, 16q
1p22 -qter, 7q, 19
24 63 /F lacrimal gland 3 /T4a N0 M0 5q12–q21 19
M: male, F: female, N: normal.
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case of myoepithelioma, a rare benign salivary gland
neoplasm that shares ACC features of myoepithelial differ-
entiation, has been reported [23]. A similar translocation has
also been shown in renal oncocytoma [24]. These findings,
together with our results, suggest that an unidentified gene
with tumor-suppressor activity might be present at chromo-
some 12q12–q13. It is possible that this unknown gene
might have functional importance for salivary gland tumors
with myoepithelial differentiation. Further studies are
required to determine the extent to which chromosome 12,
and more specifically the region telomeric to the D12S1301
marker, may play in the development or progression of
salivary gland tumors.
The CGH results of the present study, showing losses at
6q23-qter, are in agreement with the results of earlier
cytogenetic and LOH findings in ACC [5,10], and further
support the notion that deletions of genetic material at 6q
may play an essential role in the development of this
neoplasm. The chromosome 6q23-qter cytogenetic location
includes the tumor-suppressor gene PLAGL1/LOT1/ZAC
at 6q24.3. This gene was discovered to be downregulated
during the transformation of a rat ovarian epithelial cell line
[25], and was subsequently shown to be downregulated in
primary human ovarian and breast carcinomas and cell lines
[26,27]. In cell culture experiments, PLAGL1/LOT1/ZAC
has been shown to have anti -proliferative and pro-apoptotic
regulatory activities [28]. Therefore, further testing of
PLAGL1/LOT1/ZAC as a potential candidate for tumor-
specific deletion, mutation, and/or transcriptional down-
regulation in ACC is required.
The frequent losses we observed in 13q21–q22 have not
previously been reported in ACC. This genetic region is
known to be deleted in several types of cancer, such as
carcinomas of the lung, breast, prostate, and head and neck,
as well as in tumors of bone ( for review, see Ref. [29] ). This
genetic location is considerably distal to the RB1 locus
(13q14), and may indicate the presence of a novel tumor-
suppressor gene.
Gains in chromosome 19, frequently observed in the
present collection of ACC, have been reported in several
other types of carcinoma, including pancreatic [30,31],
ovarian [32], and esophageal cancer [33]. In contrast to
our findings, an earlier microsatellite LOH study by Johns et
al. [9 ], using two markers on 19q — D19S210 and
D19S246, reported a 40% rate of allelic loss in 10 ACCs.
Our analysis of ACC using seven microsatellite markers
( including the two 19q markers used in the previous study)
failed to detect chromosomal loss, supporting the conclu-
sions drawn from our CGH analysis. This discrepancy may
be attributed to differences in interpretation of LOH assays,
where allelic imbalances that occur in amplification events
are interpreted as deletions.
The finding of a larger number of genetic changes in grade
3 tumors than in grades 1 and 2 neoplasms supports the
hypothesis that more genetic alterations are required for
tumor progression. Grade 3 ACC tumors are more poorly
differentiated than grade 1 or 2 cancers in terms of tubule
formation, and tend to be more aggressive clinically. The
observation of a greater number of genetic abnormalities
associated with more aggressive forms of neoplasia has
been documented in other tumors [34].
Although specific DNA copy number abnormalities were
detected in ACC, a much lower overall number of DNA copy
number changes were seen compared with other epithelial
neoplasms arising in the upper and lower aerodigestive tract,
including nasopharyngeal carcinoma [35], head and neck
squamous carcinoma [36,37], and small cell and non–small
cell carcinomas of the lung [38–41]. Only a few ACCs
( largely those that were grade 3) had the complexity of DNA
copy number changes usually present in carcinomas of the
aerodigestive tract. Our results showing limited areas of
genetic loss in ACC are corroborated by a previous low-
density allelotype analysis, which also did not detect many
frequent deletion events [9 ]. The fact, that DNA copy
number and cytogenetic abnormalities are less frequent in
ACC, may indicate that a smaller number of genes are
involved in the development of this neoplasm than is typical
of most carcinomas. An alternative explanation for lack of
DNA copy number abnormalities is the presence of the DNA
replication error phenotype, for which an inverse correlation
with number of cytogenetic abnormalities and genetic
deletions has been found in colorectal carcinoma [42].
However, in our previous [43] and ongoing studies using
microsatellite allelotyping of ACC, no widespread micro-
satellite instability has been detected, as would be expected
with the replication error phenotype. Hence, we favor the
hypothesis that ACC develops as a result of fewer and more
specific genetic alterations.
This study is the first global survey of DNA copy number
changes in ACC, and points to the existence of possible
novel tumor-suppressor genes on 6q, 12q, and 13q. Further
LOH studies using higher-density allelotyping of micro-
satellite markers are required for chromosome 12 as well as
for chromosomes 6 and 13 to fine map regions that may
contain, as yet, unidentified tumor-suppressor genes.
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